Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Hamilton

Showing results (251-260 of 256) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 256 results.
Cancer Research|December 16, 1998
Pathogenesis of adenocarcinoma in Peutz-Jeghers syndromeS B Gruber, M M Entius, G M Petersen, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999C C Compton, L P Fielding, L J Burgart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]K L Jhaveri, X V Wang, V Makker, et al.
Cell Death and Differentiation|February 18, 2014
IRF4 and BATF are critical for CD8⁺ T-cell function following infection with LCMVM Grusdat, D R McIlwain, H C Xu, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
Pageof 26

Showing results (251-260 of 256) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 256 results.
Cancer Research|December 16, 1998
Pathogenesis of adenocarcinoma in Peutz-Jeghers syndromeS B Gruber, M M Entius, G M Petersen, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999C C Compton, L P Fielding, L J Burgart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol QK L Jhaveri, X V Wang, V Makker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]K L Jhaveri, X V Wang, V Makker, et al.
Cell Death and Differentiation|February 18, 2014
IRF4 and BATF are critical for CD8⁺ T-cell function following infection with LCMVM Grusdat, D R McIlwain, H C Xu, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
Pageof 26